Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mismatch Repair01:20

Mismatch Repair

5.3K
Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
5.3K
Mismatch Repair01:36

Mismatch Repair

37.7K
Overview
37.7K
Point and Frameshift Mutations01:30

Point and Frameshift Mutations

1.7K
Point mutations are genetic alterations involving the change of a single nucleotide base pair in DNA. Depending on how the alteration affects protein synthesis, they can lead to various consequences.Point mutations fall into the following types:Silent mutations occur when a nucleotide change does not alter the amino acid sequence due to the redundancy of the genetic code. For instance, changing ACC to ACA still encodes threonine, leaving the protein function unaffected. This occurs because...
1.7K
Mutations01:35

Mutations

30.9K
Mutations are changes in the sequence of DNA. These changes can occur spontaneously or they can be induced by exposure to environmental factors. Mutations can be characterized in a number of different ways: whether and how they alter the amino acid sequence of the protein, whether they occur over a small or large area of DNA, and whether they occur in somatic cells or germline cells.
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
30.9K
Mutations01:39

Mutations

66.2K
Overview
66.2K
Mutations01:39

Mutations

10.8K
10.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

BASECAMP-1 screening study: a model for efficient enrolment in precision oncology clinical trials.

BMJ oncology·2026
Same author

Corrigendum to "Recurrent Transcriptional Responses in AML and MDS patients Treated with Decitabine" Experimental Hematology. 2022;111:50-65.

Experimental hematology·2026
Same author

Monitoring clonal burden as an alternative to blast count for myelodysplastic neoplasm treatment response.

Leukemia·2024
Same author

Detecting HLA loss of heterozygosity within a standard diagnostic sequencing workflow for prognostic and therapeutic opportunities.

NPJ precision oncology·2024
Same author

Molecular responses in decitabine- and decitabine/ venetoclax-treated patients with acute myeloid leukemia and myelodysplastic syndromes.

Haematologica·2024
Same author

Tissue factor activates the coagulation cascade in mouse models of acute promyelocytic leukemia.

Blood advances·2023

Related Experiment Video

Updated: Apr 22, 2026

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

2.7K

Mutation position within evolutionary subclonal architecture in AML.

John S Welch1

  • 1Washington University School of Medicine, Division of Oncology, Stem Cell Biology Section, St. Louis, MO.

Seminars in Hematology
|October 15, 2014
PubMed
Summary
This summary is machine-generated.

Acute myeloid leukemia (AML) evolves via branching, with early mutations defining the founding clone and later ones appearing in subclones. Understanding this subclonal architecture is crucial for effective AML treatment strategies.

More Related Videos

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies
06:33

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies

Published on: November 10, 2023

2.0K
Simplified Intrafemoral Injections Using Live Mice Allow for Continuous Bone Marrow Analysis
06:28

Simplified Intrafemoral Injections Using Live Mice Allow for Continuous Bone Marrow Analysis

Published on: November 10, 2023

4.1K

Related Experiment Videos

Last Updated: Apr 22, 2026

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

2.7K
Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies
06:33

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies

Published on: November 10, 2023

2.0K
Simplified Intrafemoral Injections Using Live Mice Allow for Continuous Bone Marrow Analysis
06:28

Simplified Intrafemoral Injections Using Live Mice Allow for Continuous Bone Marrow Analysis

Published on: November 10, 2023

4.1K

Area of Science:

  • Hematology
  • Genomics
  • Cancer Biology

Background:

  • Cytogenetic and genomic data suggest acute myeloid leukemia (AML) develops through branching evolution.
  • This evolutionary process is particularly evident during AML relapse and disease progression.

Purpose of the Study:

  • To review current literature on AML evolution and subclonal architecture.
  • To highlight the importance of understanding mutation organization for therapeutic development.

Main Methods:

  • Review of existing literature on AML genomics.
  • Analysis of temporal genomic data, including digital sequencing, xenograft cloning, and single-cell analysis.

Main Results:

  • Most AML cases emerge through branching evolution.
  • Early mutations (e.g., t[15;17], DNMT3A, TET2) are typically in the founding clone, while later mutations (e.g., FLT3, KIT) are subclonal and can be gained/lost during relapse.
  • Mosaic hematopoiesis with DNMT3A/TET2 mutations precedes overt leukemia in some elderly individuals.

Conclusions:

  • AML evolution is characterized by a founding clone and dynamic subclones.
  • Targeting subclonal mutations may not eradicate all leukemia cells.
  • Understanding the subclonal architecture is essential for developing effective AML therapies.